

# Institute for Molecular Bioscience

**Every cure starts with a scientific discovery by someone who imagined a better future. At the Institute for Molecular Bioscience, our goal is to create a better future by making breakthrough discoveries to improve health and wellbeing.**

## INSPIRING THE NEXT GENERATION OF SCIENTISTS

Our citizen science projects are inspiring Queensland's new generation to get involved with exciting research that is helping to make a difference for their future. The Cane Toad Challenge lets people join the fight against invasive, poisonous cane toads, while Soils for Science is an Australian-first program looking for new antibiotics hiding in people's backyards.

## TRAINING AND INSPIRING THE STATE'S STEM WORKFORCE

Over the past five years, IMB has trained more than 200 PhD graduates. At IMB, PhD students are surrounded by brilliant thinkers dedicated by research, who enjoy the respect of their peers around the globe. IMB offers access to world-leading facilities, and a collegial, supportive environment where translation and entrepreneurship are encouraged and fostered.

## GLOBAL REACH

Our alumni are established across more than 40 countries, and we have more than 1400 collaborations across 50 countries. Our partners are wide and diverse. From other academic institutions, to health providers, industry, charities and governments, our partnerships find innovative solutions to local, regional and international challenges.

## THE NEXT BIG CURE

- Our researchers are discovering potentially life-saving treatments for heart attack and stroke victims using the venom of the Fraser Island funnel web spider
- IMB researchers are re-engineering "forgotten" antibiotics and exploring new molecules from around the world in the fight against superbugs
- We are spearheading a new drug and vaccine development program using micro-algae and solar energy that will create a new manufacturing industry

## AGRICULTURAL INNOVATION

- IMB researchers developed Sero-X, the world's first organic insecticide: mass-producible, non-toxic, bee-friendly and plant-based
- Our researchers are developing a next-generation anti-parasitic that protects livestock without poisoning agricultural lands
- We are creating a vaccine for the white spot virus killing wild prawns

## AT A GLANCE



**268**  
industry partners



**\$500 million**  
in research collaborations  
with industry



**12+**  
spin-out companies



**\$2 Billion+**  
invested in IP



**66**  
patents across 38  
patent families

## TIMELINE

**2001**  
Protagonist Therapeutics  
is launched as a spin-out  
company to develop  
peptide-based drugs

**2016**  
The Cane Toad Challenge  
empowers the public to help  
in the fight to eradicate the  
billions of cane toads wreaking  
havoc on our environment

**2020**  
IMB spin-out company  
Inflazome is acquired by  
Swiss pharmaceutical  
Roche for €380 million  
(approx. AU\$600 million)



**2000**

IMB is founded with  
backing from state and  
federal governments,  
UQ and the Atlantic  
Philanthropies

**2013**

A global team led by IMB  
researchers bring hope to  
children with rare genetic  
diseases when they discover  
genetic leukodystrophy

**2017**

IMB partners with Australian  
family-owned company  
Innovate Ag to create Sero-X,  
the world's first mass-  
producible organic insecticide